Home › Funds › Palo Alto Investors LP › XENE
Palo Alto Investors LP position in XENE
XENON PHARMACEUTICALS INC · Health Care
Palo Alto Investors LP reported holding 47,902 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$1.8M, representing 0.27% of its reported portfolio and ranking #44 among its reported holdings. Palo Alto Investors LP has disclosed XENE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's XENE position evolved
Palo Alto Investors LP first disclosed a stake in XENE in Q4 2025 at 96,519 shares (US$4.3M). Across 4 filings, Palo Alto Investors LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 47,902 shares valued at US$1.8M — a reduction of -3,443 shares quarter over quarter.. Notable position changes include a 47% trim in Q1 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 96.52K | $4.33M | New |
| Q1 2026 | 51.34K | $2.99M | Reduce |
| Q2 2026 | 51.34K | $3.10M | Hold |
| Q3 2026 | 47.90K | $1.78M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 26 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$204.5M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$132.3M), Affinity Asset Advisors, LLC (US$70.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.50M sh · $204.54M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 3.56M sh · $132.31M · Q3 2026
- Affinity Asset Advisors, LLC 1.90M sh · $70.67M · Q3 2026
- BRAIDWELL LP 1.71M sh · $63.54M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $60.09M · Q3 2026
- ADAR1 Capital Management, LLC 1.16M sh · $43.22M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held XENE?
Palo Alto Investors LP has disclosed XENE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Palo Alto Investors LP's current position in XENE?
As of Q3 2026, Palo Alto Investors LP holds 47.90K shares of XENE (XENON PHARMACEUTICALS INC), valued at $1.78M, representing 0.27% of its reported portfolio and ranking #44.
Has Palo Alto Investors LP been buying or selling XENE?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in XENE.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, Affinity Asset Advisors, LLC, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.